NIPT Testi

GeneMind NIGM is a Non-Invasive Prenatal Testing (NIPT) solution that analyzes cell-free DNA (cfDNA) fragments in maternal blood using Next-Generation Sequencing (NGS) technology to evaluate potential chromosomal abnormalities during early pregnancy. Fully integrated with GeneMind's advanced sequencing platforms (GenoLab M, FASTASeq 300, SURFSeq 5000), this system provides clinicians and laboratories with a highly reliable, fast, and high-precision screening infrastructure.

Detailed Information

Practical and Early-Stage Application: It can be performed safely and non-invasively as early as the 9th week of pregnancy, utilizing only a single tube (10 mL) of maternal blood sample.
Proven High Accuracy: Based on comprehensive clinical studies involving over 70,000 pregnancy data points, it has been proven to deliver an overall sensitivity of over 99% in detecting chromosomal abnormalities.
Comprehensive Screening Panels: With its clinically focused structure, it screens with high precision for Autosomal Aneuploidies (Trisomy 21, 18, and 13), specific Sex Chromosome Aneuploidies (SCA), and pathogenic microdeletion/microduplication syndromes via Standard, Plus, and Pro panel options.
Fast and Automated Workflow: The total testing time from sample preparation to report generation can be completed within 24 hours, and this duration can be reduced to as little as 16.5 hours in fully automated workflows. Bioinformatics data analysis and reporting are conducted entirely through a localized, automated system.
Flexible and Compatible Infrastructure: It operates in full compatibility with commonly used standard NGS library preparation kits and bioinformatics tools, offering both manual and fully automated workflow options tailored to the laboratory's capacity.